Catalog No.
RHC35002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
Low affinity immunoglobulin gamma Fc region receptor III-B, Fc-gamma RIII-beta, CD16-I, Fc-gamma RIII, Fc-gamma RIIIb, FcRIII, FcRIIIb, FcR-10, IgG Fc receptor III-1, CD16b, FCGR3B, CD16B, FCG3, FCGR3, IGFR3, Low affinity immunoglobulin gamma Fc region receptor III-A, IgG Fc receptor III-A, CD16-II, CD16a antigen, Fc-gamma RIII-alpha, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcgammaRIIIA, FcR-10, IgG Fc receptor III-2, CD16a, FCGR3A, CD16A, FCG3, FCGR3, IGFR3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P08637, O75015
Applications
Blocking, ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA2149
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells., PMID:40274631
Decoupling Individual Host Response and Immune Cell Engager Cytotoxic Potency., PMID:39791371
Enhancing Anti-Cancer Immune Response by Acidosis-Sensitive Nanobody Display., PMID:39254684
Enhancing Anti-Cancer Immune Response by Acidosis-sensitive Nanobody Display., PMID:39184093
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy., PMID:36685519
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells., PMID:35651607
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor., PMID:34771609
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer., PMID:34439149
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC., PMID:33999642
A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo., PMID:33636638
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells., PMID:33097838
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling., PMID:31976482
Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity., PMID:30979550
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity., PMID:30059039
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells., PMID:29357376
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity., PMID:29232309
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity., PMID:27645568
A novel bispecific antibody, BiSS, with potent anti-cancer activities., PMID:26828900
Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells., PMID:18073223
For research use only. Not for human or drug use.
